The prognostic impact of t(11;14) in multiple myeloma: A real‐world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR)
Abstract The prognostic impact of t(11;14) in multiple myeloma (MM) needs to be better understood to inform future treatment decisions. The Australian Lymphoma Leukaemia Group embarked on a retrospective, observational cohort study using real‐world data to interrogate treatment patterns and outcomes...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.742 |
| _version_ | 1797685642570760192 |
|---|---|
| author | Kenneth JC Lim Cameron Wellard Dipti Talaulikar Joanne LC Tan Joanna Loh Pratheepan Puvanakumar James A Kuzich Michelle Ho Matthew Murphy Nicole Zeglinas Michael SY Low David Routledge Andrew BM Lim Simon D Gibbs Hang Quach Sue Morgan Elizabeth Moore Slavisa Ninkovic |
| author_facet | Kenneth JC Lim Cameron Wellard Dipti Talaulikar Joanne LC Tan Joanna Loh Pratheepan Puvanakumar James A Kuzich Michelle Ho Matthew Murphy Nicole Zeglinas Michael SY Low David Routledge Andrew BM Lim Simon D Gibbs Hang Quach Sue Morgan Elizabeth Moore Slavisa Ninkovic |
| author_sort | Kenneth JC Lim |
| collection | DOAJ |
| description | Abstract The prognostic impact of t(11;14) in multiple myeloma (MM) needs to be better understood to inform future treatment decisions. The Australian Lymphoma Leukaemia Group embarked on a retrospective, observational cohort study using real‐world data to interrogate treatment patterns and outcomes in 74 MM patients with t(11;14) [t(11;14)‐MM] diagnosed over 10 years. This was compared to 159 and 111 MM patients with high‐risk IgH translocations (IgH HR‐MM) and hyperdiploidy (Hyperdiploid‐MM), respectively, from the Australian Myeloma and Related Diseases Registry. No appreciable differences in age, gender, ISS, LDH levels, 1q21 or del(17p) status, or treatment patterns were observed between groups. Median PFS‐1 was not different between groups but both t(11;14)‐MM and IgH HR‐MM had an inferior PFS‐2 vs. Hyperdiploid‐MM: median PFS–2 8.2 months, 10.0 months, and 19.8 months (p = 0.002), respectively. The 3‐year OS were 69%, 71%, and 82% (p = 0.026), respectively. In the t(11;14)‐MM group, gain or amplification of 1q21 at diagnosis predicted for poorer OS (HR 3.46, p = 0.002). Eleven patients had received venetoclax with 45% achieving better than a very good partial response. Results suggest that t(11;14) MM may confer an unfavorable risk profile and that the use of targeted therapies such as venetoclax earlier in the treatment algorithm should be explored. |
| first_indexed | 2024-03-12T00:47:25Z |
| format | Article |
| id | doaj.art-cb1202c0223440efb5b3d9e055739c68 |
| institution | Directory Open Access Journal |
| issn | 2688-6146 |
| language | English |
| last_indexed | 2024-03-12T00:47:25Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | eJHaem |
| spelling | doaj.art-cb1202c0223440efb5b3d9e055739c682023-09-14T15:30:47ZengWileyeJHaem2688-61462023-08-014363964610.1002/jha2.742The prognostic impact of t(11;14) in multiple myeloma: A real‐world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR)Kenneth JC Lim0Cameron Wellard1Dipti Talaulikar2Joanne LC Tan3Joanna Loh4Pratheepan Puvanakumar5James A Kuzich6Michelle Ho7Matthew Murphy8Nicole Zeglinas9Michael SY Low10David Routledge11Andrew BM Lim12Simon D Gibbs13Hang Quach14Sue Morgan15Elizabeth Moore16Slavisa Ninkovic17Department of Haematology St Vincent's Hospital Melbourne Melbourne AustraliaSchool of Public Health and Preventive Medicine Monash University Melbourne AustraliaDepartment of Haematology The Canberra Hospital Canberra AustraliaDepartment of HaematologyThe Alfred HospitalMelbourneAustraliaDepartment of HaematologyMonash HealthMelbourneAustraliaClinical HaematologyPeter MacCallum Cancer Centre and Royal Melbourne HospitalMelbourneAustraliaDepartment of HaematologyAustin Health and Olivia Newton John Cancer Research InstituteMelbourneAustraliaDepartment of Haematology The Canberra Hospital Canberra AustraliaDepartment of HaematologyEastern HealthMelbourneAustraliaDepartment of Haematology St Vincent's Hospital Melbourne Melbourne AustraliaDepartment of HaematologyMonash HealthMelbourneAustraliaClinical HaematologyPeter MacCallum Cancer Centre and Royal Melbourne HospitalMelbourneAustraliaDepartment of HaematologyAustin Health and Olivia Newton John Cancer Research InstituteMelbourneAustraliaDepartment of HaematologyEastern HealthMelbourneAustraliaDepartment of Haematology St Vincent's Hospital Melbourne Melbourne AustraliaDepartment of HaematologyThe Alfred HospitalMelbourneAustraliaSchool of Public Health and Preventive Medicine Monash University Melbourne AustraliaDepartment of Haematology St Vincent's Hospital Melbourne Melbourne AustraliaAbstract The prognostic impact of t(11;14) in multiple myeloma (MM) needs to be better understood to inform future treatment decisions. The Australian Lymphoma Leukaemia Group embarked on a retrospective, observational cohort study using real‐world data to interrogate treatment patterns and outcomes in 74 MM patients with t(11;14) [t(11;14)‐MM] diagnosed over 10 years. This was compared to 159 and 111 MM patients with high‐risk IgH translocations (IgH HR‐MM) and hyperdiploidy (Hyperdiploid‐MM), respectively, from the Australian Myeloma and Related Diseases Registry. No appreciable differences in age, gender, ISS, LDH levels, 1q21 or del(17p) status, or treatment patterns were observed between groups. Median PFS‐1 was not different between groups but both t(11;14)‐MM and IgH HR‐MM had an inferior PFS‐2 vs. Hyperdiploid‐MM: median PFS–2 8.2 months, 10.0 months, and 19.8 months (p = 0.002), respectively. The 3‐year OS were 69%, 71%, and 82% (p = 0.026), respectively. In the t(11;14)‐MM group, gain or amplification of 1q21 at diagnosis predicted for poorer OS (HR 3.46, p = 0.002). Eleven patients had received venetoclax with 45% achieving better than a very good partial response. Results suggest that t(11;14) MM may confer an unfavorable risk profile and that the use of targeted therapies such as venetoclax earlier in the treatment algorithm should be explored.https://doi.org/10.1002/jha2.742BCL2multiple myelomat(11;14)venetoclax |
| spellingShingle | Kenneth JC Lim Cameron Wellard Dipti Talaulikar Joanne LC Tan Joanna Loh Pratheepan Puvanakumar James A Kuzich Michelle Ho Matthew Murphy Nicole Zeglinas Michael SY Low David Routledge Andrew BM Lim Simon D Gibbs Hang Quach Sue Morgan Elizabeth Moore Slavisa Ninkovic The prognostic impact of t(11;14) in multiple myeloma: A real‐world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR) eJHaem BCL2 multiple myeloma t(11;14) venetoclax |
| title | The prognostic impact of t(11;14) in multiple myeloma: A real‐world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR) |
| title_full | The prognostic impact of t(11;14) in multiple myeloma: A real‐world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR) |
| title_fullStr | The prognostic impact of t(11;14) in multiple myeloma: A real‐world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR) |
| title_full_unstemmed | The prognostic impact of t(11;14) in multiple myeloma: A real‐world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR) |
| title_short | The prognostic impact of t(11;14) in multiple myeloma: A real‐world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR) |
| title_sort | prognostic impact of t 11 14 in multiple myeloma a real world analysis from the australian lymphoma leukaemia group allg and the australian myeloma and related diseases registry mrdr |
| topic | BCL2 multiple myeloma t(11;14) venetoclax |
| url | https://doi.org/10.1002/jha2.742 |
| work_keys_str_mv | AT kennethjclim theprognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT cameronwellard theprognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT diptitalaulikar theprognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT joannelctan theprognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT joannaloh theprognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT pratheepanpuvanakumar theprognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT jamesakuzich theprognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT michelleho theprognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT matthewmurphy theprognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT nicolezeglinas theprognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT michaelsylow theprognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT davidroutledge theprognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT andrewbmlim theprognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT simondgibbs theprognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT hangquach theprognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT suemorgan theprognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT elizabethmoore theprognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT slavisaninkovic theprognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT kennethjclim prognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT cameronwellard prognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT diptitalaulikar prognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT joannelctan prognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT joannaloh prognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT pratheepanpuvanakumar prognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT jamesakuzich prognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT michelleho prognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT matthewmurphy prognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT nicolezeglinas prognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT michaelsylow prognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT davidroutledge prognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT andrewbmlim prognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT simondgibbs prognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT hangquach prognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT suemorgan prognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT elizabethmoore prognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr AT slavisaninkovic prognosticimpactoft1114inmultiplemyelomaarealworldanalysisfromtheaustralianlymphomaleukaemiagroupallgandtheaustralianmyelomaandrelateddiseasesregistrymrdr |